4,944 results match your criteria European Journal of Nuclear Medicine and Molecular Imaging[Journal]


The good rays: let them shine!

Eur J Nucl Med Mol Imaging 2018 Dec 17. Epub 2018 Dec 17.

Department of Nuclear Medicine, Odense University Hospital, 5000, Odense C, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4233-7DOI Listing
December 2018

A new frontier for amyloid PET imaging: multiple sclerosis.

Eur J Nucl Med Mol Imaging 2018 Dec 15. Epub 2018 Dec 15.

IRCCS Ospedale Policlinico San Martino, L.go R. Benzi, 10, 16132, Genoa, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4232-8
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4232-8DOI Listing
December 2018
1 Read

Severe posterior hypometabolism but normal perfusion in a patient with chronic fatigue syndrome/myalgic encephalomyelitis revealed by PET/MRI.

Eur J Nucl Med Mol Imaging 2018 Dec 14. Epub 2018 Dec 14.

SyMPTOm PET/MRI Platform, Nuclear Medicine Department, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, 51 avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4229-3DOI Listing
December 2018

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

Eur J Nucl Med Mol Imaging 2018 Dec 14. Epub 2018 Dec 14.

Service de Médecine Nucléaire, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4221-yDOI Listing
December 2018

Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study.

Eur J Nucl Med Mol Imaging 2018 Dec 13. Epub 2018 Dec 13.

Oncology Division, Rambam Health Care Campus, 8 Ha'Aliya Hashniya, and Technion - Israel Institute of Technology, 1 Efron Street, Haifa, Israel.

Purpose: Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitaxel.

Methods: Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4234-6DOI Listing
December 2018

The diagnostic accuracy of F-FDG PET/CT in diagnosing fracture-related infections.

Eur J Nucl Med Mol Imaging 2018 Dec 7. Epub 2018 Dec 7.

Department of Trauma Surgery, Utrecht University, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

Purpose: F-Fluorodeoxyglucose positron emission tomography (F-FDG PET/CT) is frequently used to diagnose fracture-related infections (FRIs), but its diagnostic performance in this field is still unknown. The aims of this study were: (1) to assess the diagnostic performance of qualitative assessment of F-FDG PET/CT scans in diagnosing FRI, (2) to establish the diagnostic performance of standardized uptake values (SUVs) extracted from F-FDG PET/CT scans and to determine their associated optimal cut-off values, and (3) to identify variables that predict a false-positive (FP) or false-negative (FN) F-FDG PET/CT result.

Methods: This retrospective cohort study included all patients with suspected FRI undergoing F-FDG PET/CT between 2011 and 2017 in two level-1 trauma centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4218-6DOI Listing
December 2018

Predicting PD-1/PD-L1 status in bladder cancer with F-FDG PET?

Eur J Nucl Med Mol Imaging 2018 Dec 11. Epub 2018 Dec 11.

Departments of Radiology and Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4224-8DOI Listing
December 2018

Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.

Eur J Nucl Med Mol Imaging 2018 Dec 8. Epub 2018 Dec 8.

Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str.3, 72076, Tuebingen, Germany.

Purpose: To demonstrate the clinical use of FDG-PET/MRI for monitoring enlargement and metabolism of plexiform neurofibromas (PNF) in patients with neurofibromatosis type 1 (NF1), in whom the development of a malignant peripheral nerve sheath tumor (MPNST) is often a life limiting event.

Methods: NF1 patients who underwent a simultaneous FDG-PET/MRI examination in our institution from September 2012 to February 2018 were included. Indication was suspicion of malignant transformation of a PNF to MPNST. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4227-5DOI Listing
December 2018

F-FDG PET/CT diagnostic performance in solitary and multiple pulmonary nodules detected in patients with previous cancer history: reports of 182 nodules.

Eur J Nucl Med Mol Imaging 2018 Dec 8. Epub 2018 Dec 8.

Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Francesco Vito, 1, 00168, Roma, Italia.

Purpose: In oncological patients, F-FDG PET/CT performance for pulmonary nodules' characterization is not well-established. Thus, the purpose of this study was to evaluate the F-FDG PET/CT diagnostic performance in pulmonary nodules detected during follow-up in oncological patients and the relationship between malignancy and nodules' characteristics.

Methods: We retrospectively evaluated 182 pulmonary nodules (121 solitary, 61 multiple; mean size = 16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4226-6DOI Listing
December 2018

External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy.

Eur J Nucl Med Mol Imaging 2018 Dec 7. Epub 2018 Dec 7.

Radiation Oncology Department, University Hospital, Brest, France.

Purpose: The aim of this study was to validate previously developed radiomics models relying on just two radiomics features from F-fluorodeoxyglucose positron emission tomography (PET) and magnetic resonance imaging (MRI) images for prediction of disease free survival (DFS) and locoregional control (LRC) in locally advanced cervical cancer (LACC).

Methods: Patients with LACC receiving chemoradiotherapy were enrolled in two French and one Canadian center. Pre-treatment imaging was performed for each patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4231-9DOI Listing
December 2018

Monitoring response of advanced Merkel cell carcinoma to Avelumab with F-FDG PET/CT.

Eur J Nucl Med Mol Imaging 2018 Dec 7. Epub 2018 Dec 7.

Nuclear Medicine Unit, ICS Maugeri SpA SB IRCCS, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4230-xDOI Listing
December 2018

Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Eur J Nucl Med Mol Imaging 2018 Dec 7. Epub 2018 Dec 7.

Nuclear Medicine Department, University Hospital, Caen, France.

An error occurred in the labelling of Fig. 3, where math symbols for SUV thresholds were inverted in panel b when the EARL threshold was applied to the PSF dataset and vice versa. This figure should read as follows: Fig. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4216-8DOI Listing
December 2018

Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by Ga-DOTATATE PET/CT.

Eur J Nucl Med Mol Imaging 2018 Dec 5. Epub 2018 Dec 5.

Department of Nuclear Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4228-4DOI Listing
December 2018
1 Read

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0.

Eur J Nucl Med Mol Imaging 2018 Dec 5. Epub 2018 Dec 5.

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4207-9DOI Listing
December 2018

Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [F] fluorodeoxyglucose and [F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging.

Eur J Nucl Med Mol Imaging 2018 Dec 1. Epub 2018 Dec 1.

Cancer Imaging Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Purpose: To compare [F]-fluorodeoxyglucose (FDG) and [F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer.

Patients And Methods: Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUV); WB-MRI: median apparent diffusion coefficient (ADC)] at baseline and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CT was also performed if 8-week SUV increased. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4223-9DOI Listing
December 2018

Personalized Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Eur J Nucl Med Mol Imaging 2018 Nov 30. Epub 2018 Nov 30.

Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, Canada.

Purpose: Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4209-7DOI Listing
November 2018

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease.

Eur J Nucl Med Mol Imaging 2018 Dec 4. Epub 2018 Dec 4.

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, 141 52, Stockholm, Sweden.

Purpose: The spatial resolution of F-fluorodeoxyglucose PET does not allow the specific cellular origin of its signal to be determined, but it is commonly accepted that transport and trapping of F-fluorodeoxyglucose reflects neuronal glucose metabolism. The main frameworks for the diagnosis of Alzheimer's disease suggest that hypometabolism measured with F-fluorodeoxyglucose PET is a biomarker of neuronal injury and neurodegeneration. There is preclinical evidence to suggest that astrocytes contribute, at least partially, to the in vivo F-fluorodeoxyglucose PET signal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4217-7DOI Listing
December 2018

Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma.

Eur J Nucl Med Mol Imaging 2018 Nov 29. Epub 2018 Nov 29.

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for the tumor cell targeting. Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter Bi allows for selective irradiation and killing of tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4225-7DOI Listing
November 2018
3 Reads

Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.

Eur J Nucl Med Mol Imaging 2018 Nov 28. Epub 2018 Nov 28.

Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.

Purpose: The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine.

Methods: Of 327 patients imaged, 223 were referred for recurrent PCA and gave written informed consent for further analysis of their data for this retrospective consecutive cohort analysis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4203-0
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4203-0DOI Listing
November 2018
3 Reads

Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.

Eur J Nucl Med Mol Imaging 2018 Nov 28. Epub 2018 Nov 28.

Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Purpose: Ipilimumab induces durable remission in about 15-20% of patients with metastatic melanoma. However, reliable predictors of response to ipilimumab are currently lacking. Whole-body metabolic tumor volume (wMTV) has been shown to be a strong prognostic factor in a variety of malignancies treated with chemotherapy, but few results have been reported for patients treated with immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4211-0DOI Listing
November 2018

Outcome and safety of rechallenge [Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Eur J Nucl Med Mol Imaging 2018 Nov 24. Epub 2018 Nov 24.

Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany.

Background: Data are sparse regarding the feasibility of radioligand therapy (RLT) with [Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited from this therapy.

Materials And Methods: Patients who received rechallenge therapy at our department from January 2015 to March 2018 were assessed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4222-x
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4222-xDOI Listing
November 2018
14 Reads

First steps in an uncharted territory by WFNMB.

Eur J Nucl Med Mol Imaging 2018 Nov 22. Epub 2018 Nov 22.

World Federation of Nuclear Medicine and Biology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4212-zDOI Listing
November 2018

F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Eur J Nucl Med Mol Imaging 2018 Nov 19. Epub 2018 Nov 19.

Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA.

Purpose: Metabolic imaging using [F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4214-xDOI Listing
November 2018
3 Reads

Deauville score: the Phoenix rising from ashes.

Eur J Nucl Med Mol Imaging 2018 Nov 14. Epub 2018 Nov 14.

Radiology, Lysa Imaging and Haematology, Hôpitaux Universitaires Henri Mondor, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4215-9DOI Listing
November 2018

Comparing diagnostic accuracy of F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections.

Eur J Nucl Med Mol Imaging 2018 Nov 13. Epub 2018 Nov 13.

Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich / University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland.

Background: To evaluate the diagnostic accuracy of positron emission tomography/computed tomography with F-fluorodeoxyglucose (PET/CT), contrast-enhanced CT (CE-CT), and a combined imaging approach (CE-PET/CT) in patients with suspected vascular graft infection (VGI).

Methods: PET/CT and CE-CT were performed prospectively in 23 patients with suspected VGI. Diagnostic accuracy for PET/CT was assessed by using previously suggested cut-off points for maximum standardized uptake values (SUV) measured in the vicinity of the graft. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4205-y
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4205-yDOI Listing
November 2018
6 Reads

Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases.

Eur J Nucl Med Mol Imaging 2018 Nov 10. Epub 2018 Nov 10.

Department of Nuclear Medicine and Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital and Chang Gung University, 5 Fu-Shin Street, Kueishan, Taoyuan, 333, Taiwan.

Purpose: The role of brain FDG-PET in patients with lung cancer and brain metastases remains unclear. Here, we sought to determine the prognostic significance of whole-body PET/CT plus brain PET/MR in predicting the time to neurological progression (nTTP) and overall survival (OS) in this patient group.

Methods: Of 802 patients with non-small cell lung cancer who underwent primary staging by a single-day protocol of whole-body PET/CT plus brain PET/MR, 72 cases with adenocarcinoma and brain metastases were enrolled for a prognostic analysis of OS. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4210-1
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4210-1DOI Listing
November 2018
5 Reads

Minimal rest activity for SPECT myocardial perfusion imaging in a one-day stress-first protocol.

Eur J Nucl Med Mol Imaging 2018 Nov 8. Epub 2018 Nov 8.

Department of Nuclear Medicine, Isala Hospital, PO Box 10400, 8000 GK, Zwolle, The Netherlands.

Purpose: Guidelines propose different rest-stress activity ratios (RSAR) for one-day stress-first SPECT myocardial perfusion imaging (MPI), but evidence is limited. Our aim was to determine and validate the minimal RSAR resulting in the same diagnostic outcome in one-day stress-first SPECT MPI.

Methods: Forty-seven patients referred for rest after stress CZT-SPECT/CT MPI were prospectively included. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4206-x
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4206-xDOI Listing
November 2018
4 Reads

Challenges are opportunities.

Authors:
Arturo Chiti

Eur J Nucl Med Mol Imaging 2019 Jan;46(1)

Humanitas University and Humanitas Research Center, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4213-yDOI Listing
January 2019

Why should we be concerned about a "g"?

Eur J Nucl Med Mol Imaging 2018 Nov 6. Epub 2018 Nov 6.

Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4204-zDOI Listing
November 2018
1 Read

Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

Eur J Nucl Med Mol Imaging 2018 Nov 1. Epub 2018 Nov 1.

KCL and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, Kings College London at St Thomas' Hospital, Kings Health Partners, 4th floor Lambeth Wing, Westminster Bridge Road, London, SE1 7EH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4200-3DOI Listing
November 2018

Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease.

Eur J Nucl Med Mol Imaging 2018 Oct 31. Epub 2018 Oct 31.

Department of Neuroscience (DINOGMI), IRCCS Polyclinic San Martino-IST, University of Genoa, Genoa, Italy.

Purpose: The aim of this study was to verify the reliability and generalizability of an automatic tool for the detection of Alzheimer-related hypometabolic pattern based on a Support-Vector-Machine (SVM) model analyzing F-fluorodeoxyglucose (FDG) PET data.

Methods: The SVM model processed metabolic data from anatomical volumes of interest also considering interhemispheric asymmetries. It was trained on a homogeneous dataset from a memory clinic center and tested on an independent multicentric dataset drawn from the Alzheimer's Disease Neuroimaging Initiative. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4197-7
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4197-7DOI Listing
October 2018
2 Reads

Prognostic analysis of interim F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy.

Eur J Nucl Med Mol Imaging 2018 Oct 31. Epub 2018 Oct 31.

Department of Nuclear Medicine, First Hospital of Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, China.

Objectives: F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is routinely used in diffuse large B cell lymphoma (DLBCL) for staging, assessment of remission and recurrence, and estimation of therapeutic efficacy. In this study, we aimed to assess the role of an early interim PET/computed tomography (CT) in the evaluation of response in DLBCL.

Methods: Sixty primary DLBCL patients (31 females) were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4198-6DOI Listing
October 2018
1 Read

Performance of F-FDG PET/MRI and F-FDG PET/CT for T and N staging in patients with non-small-cell lung cancer.

Eur J Nucl Med Mol Imaging 2018 Oct 30. Epub 2018 Oct 30.

CHU de Bordeaux, F-33000, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4201-2DOI Listing
October 2018
1 Read

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

Eur J Nucl Med Mol Imaging 2018 Oct 29. Epub 2018 Oct 29.

Medical Oncology, Centre Eugène Marquis, Rennes, France.

Purpose: Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality.

Methods: We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4199-5
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4199-5DOI Listing
October 2018
1 Read

Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Eur J Nucl Med Mol Imaging 2018 Oct 29. Epub 2018 Oct 29.

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose: Somatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist Ga-DOTA-JR11 for PET imaging of NETs.

Methods: Twenty patients with advanced NETs underwent whole-body PET/CT imaging 60 min after injection of 169 MBq (median) Ga-DOTA-JR11 as part of a prospective study. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4193-y
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4193-yDOI Listing
October 2018
8 Reads

Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Eur J Nucl Med Mol Imaging 2019 Jan 22;46(1):31-39. Epub 2018 Oct 22.

Metropolitan Nuclear Medicine of Bologna, University of Bologna, Bologna, Italy.

Objectives: The primary objective was the evaluation of Gallium 68 (Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) detection rate, for identifying the site of prostate cancer (PCa) relapse (local vs systemic), stratifying the population according to different clinical stages of biochemical recurrence (BCR). Secondary aims were: 1) to evaluate the association of clinical/pathologic features and Ga-PSMA-11 PET/CT detection rate, 2) to compare Ga-PSMA-11 PET/CT with other imaging procedures, and 3) to evaluate the positive predictive value (PPV) in a per-patient analysis.

Material And Methods: This population was enrolled through a prospective, open label, single-center trial performed at the Nuclear Medicine of the University Hospital of Bologna (Eudract: 2015-004589-27 OsSC). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4189-7
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4189-7DOI Listing
January 2019
8 Reads

Effect of blood glucose level on standardized uptake value (SUV) in F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements.

Eur J Nucl Med Mol Imaging 2019 Jan 22;46(1):224-237. Epub 2018 Oct 22.

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Objectives: To evaluate the effect of pre-scan blood glucose levels (BGL) on standardized uptake value (SUV) in F-FDG-PET scan.

Methods: A literature review was performed in the MEDLINE, Embase, and Cochrane library databases. Multivariate regression analysis was performed on individual datum to investigate the correlation of BGL with SUV and SUV adjusting for sex, age, body mass index (BMI), diabetes mellitus diagnosis, F-FDG injected dose, and time interval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4194-xDOI Listing
January 2019
1 Read
5.383 Impact Factor

Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections.

Eur J Nucl Med Mol Imaging 2019 Jan 21;46(1):174-183. Epub 2018 Oct 21.

Medical Imaging Center, Departments of Nuclear Medicine and Molecular Imaging and Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Introduction: Invasive fungal infections (IFIs) occur mostly in immunosuppressed patients and can be life-threatening. Inadequate treatment is associated with high morbidity and mortality. We examined the role of 2-fluorodeoxyglucose positron emission tomography integrated with CT (FDG-PET/CT) in monitoring IFIs and therapy decision-making, and evaluated the role of baseline metabolic parameters in predicting the metabolic response. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4192-z
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4192-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267682PMC
January 2019
5 Reads

Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.

Eur J Nucl Med Mol Imaging 2018 Oct 21. Epub 2018 Oct 21.

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.

Purpose: The disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid (Aβ) levels, amyloid tracer uptake, and brain volumes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4182-1DOI Listing
October 2018
1 Read

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).

Eur J Nucl Med Mol Imaging 2018 Oct 20. Epub 2018 Oct 20.

Centre for Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Purpose: Rectal neuroendocrine neoplasia (NEN) is more common than other NEN origins, but is less commonly metastatic. However, when present, distant disease carries a particularly poor prognosis. Evidence guiding optimal treatment of such patients is lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4196-8DOI Listing
October 2018
5.383 Impact Factor

Osteoid osteoma: multimodality imaging with focus on hybrid imaging.

Eur J Nucl Med Mol Imaging 2018 Oct 19. Epub 2018 Oct 19.

Department of Radiology and Nuclear Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland.

Osteoid osteoma is a painful, benign, osteoblastic lesion that occurs in younger patients and affects the extremities or the axial skeleton. While plain film findings may suggest the diagnosis, in complex anatomical regions such as the spine, pelvis, wrist and foot advanced imaging modalities are often required. A typical nidus surrounded by sclerosis or cortical thickening characterizes osteoid osteoma on plain radiography and CT. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4181-2
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4181-2DOI Listing
October 2018
6 Reads

FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.

Eur J Nucl Med Mol Imaging 2018 Oct 16. Epub 2018 Oct 16.

Institute of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, 52425, Juelich, Germany.

Purpose: Areas of contrast enhancement (CE) on MRI are usually the target for resection or radiotherapy target volume definition in glioblastomas. However, the solid tumour mass may extend beyond areas of CE. Amino acid PET can detect parts of the tumour that show no CE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4188-8DOI Listing
October 2018

Use of F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis.

Eur J Nucl Med Mol Imaging 2018 Oct 16. Epub 2018 Oct 16.

Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Purpose: F-fluorodeoxyglocose positron emission tomography (FDG PET) plays a significant role in the diagnosis of cardiac sarcoidosis (CS). Texture analysis is a group of computational methods for evaluating the inhomogeneity among adjacent pixels or voxels. We investigated whether texture analysis applied to myocardial FDG uptake has diagnostic value in patients with CS. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4195-9
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4195-9DOI Listing
October 2018
11 Reads

Myocardial MIBG scintigraphy in genetic Parkinson's disease as a model for Lewy body disorders.

Eur J Nucl Med Mol Imaging 2018 Oct 15. Epub 2018 Oct 15.

Neurodegenerative Diseases Group, Biocruces-Bizkaia Health Research Institute, Plaza de Cruces 12, CP 48903, Barakaldo, Bizkaia, Spain.

Purpose: To identify myocardial sympathetic denervation patterns suggestive of Lewy body (LB) pathology in patients with genetic and idiopathic parkinsonisms by I-metaiodobenzylguanidine (MIBG) scintigraphy.

Methods: We retrospectively analysed myocardial MIBG images acquired with a dual-head gamma camera and low-energy high-resolution collimator (LEHR) in 194 patients with suspected synucleinopathy or atypical parkinsonism, including 34 with genetic Parkinson's disease (PD; 4 PARK1, 8 PARK2 and 22 PARK8), 85 with idiopathic PD (iPD), 6 with idiopathic REM sleep behaviour disorder (iRBD), 17 with dementia with LB (DLB), 40 with multiple system atrophy (MSA) and 12 with progressive supranuclear palsy (PSP), and in 45 healthy controls. We calculated heart-to-mediastinum MIBG uptake ratios (HMR) at 15 min and 4 h (HMR4H) for the LEHR and standardized medium-energy collimators, to obtain classification accuracies and optimal cut-off values for HMR using supervised classification and ROC analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4183-0DOI Listing
October 2018
7 Reads

Correction to: Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.

Eur J Nucl Med Mol Imaging 2019 Jan;46(1):266

Metropolitan Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Via Pietro Albertoni 15, 40138, Bologna, Italy.

The author names in the original version of this article were inversed. Correct author names were reflected here. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4190-1
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4190-1DOI Listing
January 2019
3 Reads

Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

Authors:
Hossein Jadvar

Eur J Nucl Med Mol Imaging 2019 Jan 11;46(1):8-10. Epub 2018 Oct 11.

Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA, 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4191-0DOI Listing
January 2019

Target identification for the diagnosis and intervention of vulnerable atherosclerotic plaques beyond F-fluorodeoxyglucose positron emission tomography imaging: promising tracers on the horizon.

Eur J Nucl Med Mol Imaging 2019 Jan 9;46(1):251-265. Epub 2018 Oct 9.

Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC+), 6200 MD, Maastricht, The Netherlands.

Cardiovascular disease is the major cause of morbidity and mortality in developed countries and atherosclerosis is the major cause of cardiovascular disease. Atherosclerotic lesions obstruct blood flow in the arterial vessel wall and can rupture leading to the formation of occlusive thrombi. Conventional diagnostic tools are still of limited value for identifying the vulnerable arterial plaque and for predicting its risk of rupture and of releasing thromboembolic material. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4176-z
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4176-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267660PMC
January 2019
1 Read

Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients.

Eur J Nucl Med Mol Imaging 2018 Oct 5. Epub 2018 Oct 5.

Center for Radiopharmaceutical Sciences of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093, Zurich, Switzerland.

Purpose: The aim of the present study was to determine the expression levels of mGluR5 in different mouse strains after induction of neuroinflammation by lipopolysaccharide (LPS) challenge and in the brains of patients with Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) post mortem to investigate mGluR5 expression in human neurodegenerative diseases.

Methods: C57BL/6 and CD1 mice were injected intraperitoneally with either 10 mg/kg LPS or saline. mGluR5 and TSPO mRNA levels were measured after 1 and 5 days by qPCR, and mGluR5 protein levels were determined by PET imaging with the mGluR5-specific radiotracer [F]PSS232. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4179-9
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4179-9DOI Listing
October 2018
12 Reads

FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Eur J Nucl Med Mol Imaging 2019 Jan 5;46(1):238-250. Epub 2018 Oct 5.

EANM Oncology Committee, Vienna, Austria.

This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4171-4
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4171-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267687PMC
January 2019
1 Read